In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV) in opioid users with central sleep apnea (CSA).
Treating sleep-disordered breathing with methods such as adaptive sero-ventilation (ASV) could potentially improve areas such as cognitive function and productivity in patients with central sleep apnea (CSA) using opioids, according to Adam Benjafield, PhD, vice president of medical affairs at ResMed. Benjafield also discussed the impact opioids have on patients with CSA.
In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with ASV in opioid users.
Transcript
Could initiating ASV improve other outcomes in opioid users with CSA, besides sleepiness and disease-specific quality of life? For instance, could it improve cognitive function or pain levels?
There is evidence that suggests apart from sleepiness and disease specific quality of life, which is what we specifically measured in the READ-ASV registry that other aspects that when you treat sleep disordered breathing, such as central sleep apnea, there can be improvements in cognitive function. There can be improvements in productivity and other aspects as well, by having that good quality sleep, then allows better overall health.
With the opioid crisis in the US, what insights does this registry provide on that patient group?
This is a really important point. There's not a lot of clinical literature that has been published on the topic of opioid induced central sleep apnea, and the impact of treating that central sleep apnea. What we found with this registry, this specific subgroup of patients had significant improvements in both sleepiness as well as disease specific quality of life when they had their central sleep apnea treated by adaptive servo ventilation. This highlighted that there is sometimes very difficult to manage population can get significant improvements in their quality of life by having their opioid induced central sleep apnea appropriately treated, which is what the ASV therapy is designed to do.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More